22nd Century Group (XXII) Expected to Announce Earnings on Tuesday

22nd Century Group (NASDAQ:XXII) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect 22nd Century Group to post earnings of ($2.10) per share and revenue of $4.05 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:00 AM ET.

22nd Century Group Stock Performance

Shares of XXII opened at $3.51 on Tuesday. The stock has a 50 day moving average price of $6.61 and a two-hundred day moving average price of $14.74. The firm has a market capitalization of $1.79 million, a P/E ratio of 0.00 and a beta of 1.03. 22nd Century Group has a 52 week low of $3.38 and a 52 week high of $841.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 22nd Century Group in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Trading of 22nd Century Group

A hedge fund recently bought a new stake in 22nd Century Group stock. Geode Capital Management LLC purchased a new position in shares of 22nd Century Group, Inc (NASDAQ:XXII) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned about 9.12% of 22nd Century Group as of its most recent SEC filing. 18.06% of the stock is owned by institutional investors and hedge funds.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.